CN116891810A - Probiotic composition with blood sugar reducing effect and probiotic prebiotic composite preparation - Google Patents
Probiotic composition with blood sugar reducing effect and probiotic prebiotic composite preparation Download PDFInfo
- Publication number
- CN116891810A CN116891810A CN202211561125.2A CN202211561125A CN116891810A CN 116891810 A CN116891810 A CN 116891810A CN 202211561125 A CN202211561125 A CN 202211561125A CN 116891810 A CN116891810 A CN 116891810A
- Authority
- CN
- China
- Prior art keywords
- freeze
- lactobacillus fermentum
- dried powder
- bifidobacterium
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 90
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 90
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 65
- 239000008280 blood Substances 0.000 title claims abstract description 54
- 210000004369 blood Anatomy 0.000 title claims abstract description 54
- 230000001603 reducing effect Effects 0.000 title claims abstract description 37
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 35
- 239000002131 composite material Substances 0.000 title claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 128
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 115
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 115
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 74
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 74
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 55
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 55
- 244000005700 microbiome Species 0.000 claims abstract description 27
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 21
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 21
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 13
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 12
- 238000009472 formulation Methods 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
- 239000008103 glucose Substances 0.000 claims description 14
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 12
- 238000004321 preservation Methods 0.000 claims description 10
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 9
- 238000009629 microbiological culture Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 230000002195 synergetic effect Effects 0.000 abstract description 9
- 230000035755 proliferation Effects 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 5
- 239000005913 Maltodextrin Substances 0.000 description 24
- 229920002774 Maltodextrin Polymers 0.000 description 24
- 229940035034 maltodextrin Drugs 0.000 description 24
- 239000001963 growth medium Substances 0.000 description 23
- 239000008176 lyophilized powder Substances 0.000 description 23
- 239000007788 liquid Substances 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000002156 mixing Methods 0.000 description 14
- 239000002054 inoculum Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 7
- 238000007710 freezing Methods 0.000 description 7
- 230000008014 freezing Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 229940116269 uric acid Drugs 0.000 description 7
- 241000252212 Danio rerio Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000013923 monosodium glutamate Nutrition 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000010802 sludge Substances 0.000 description 4
- 229940073490 sodium glutamate Drugs 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 241000185999 Bifidobacterium longum subsp. longum Species 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 241000193171 Clostridium butyricum Species 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000006792 cys medium Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229960002827 pioglitazone hydrochloride Drugs 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241000702462 Akkermansia muciniphila Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013225 high-fat diet-induced obese mouse model Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the field of microorganisms, and discloses a probiotic composition and a probiotic prebiotic composite preparation with a blood sugar reducing effect. The probiotic composition comprises bifidobacterium longum WH2270, bifidobacterium animalis WH2276, lactobacillus fermentum A and lactobacillus fermentum B; the probiotic prebiotic compound preparation comprises bifidobacterium longum WH2270 freeze-dried powder, bifidobacterium animalis WH2276 freeze-dried powder, lactobacillus fermentum A freeze-dried powder, lactobacillus fermentum B freeze-dried powder, fructo-oligosaccharide and galacto-oligosaccharide. Firstly, after four strains are compounded, the strain proliferation and blood sugar reducing effect can be synergistically enhanced, and the blood sugar reducing effect can be remarkably enhanced. Based on the probiotic composition, the galacto-oligosaccharide and the fructo-oligosaccharide are further compounded, the components fully play a synergistic effect, the efficacy is better than that of the independent materials, and the blood sugar reducing efficacy can be further and obviously enhanced.
Description
Technical Field
The invention relates to the field of microorganisms, in particular to a probiotic composition with a blood sugar reducing effect and a probiotic prebiotic composite preparation.
Background
Diabetes is a chronic metabolic disease characterized by hyperglycemia, also known as an intangible killer, because hyperglycemia is harmful to the human body, but is difficult to detect. Long-term hyperglycemic symptoms can cause a range of chronic complications, such as retinopathy, nephropathy, foot ulcers, and the like. For the medicine for treating diabetes, the type I diabetes patient injects insulin to control blood sugar; type II diabetics take drugs including biguanides, sulfonylureas, etc., but have side effects such as excessive decrease in blood glucose level, causing hypoglycemia, and also strong hunger sensation, causing failure of diet control, and promoting obesity; and biguanides are prone to lactic acidosis.
There are many reports of probiotics on the study of blood glucose regulation. For example, patent CN202210709617 reports a bifidobacterium longum 070103, and fermented milk prepared by fermenting the strain has the effects of reducing blood sugar and blood fat; patent CN202110685626 reports a bifidobacterium longum MI-186, and a gastric lavage high fat diet induced obese mouse model, and finds that the strain has the effects of reducing blood fat and blood sugar; patent CN202111261188 reports that a bifidobacterium longum NSP008, a gastric lavage high fat diet induced insulin resistant mouse model, can improve glucose tolerance and reduce blood glucose in mice.
Diabetes mellitus often occurs with blood uric acid and dyslipidemia and obesity. There are also many reports on studies of probiotics on blood uric acid regulation, blood lipid regulation and obesity reduction. For example, patent CN202210602874 reports that a bifidobacterium lactis SF-B21 can effectively reduce uric acid content in human body; patent CN202111480237 reports a strain of lactobacillus fermentum which can effectively inhibit the intake of exogenous uric acid and the increase of endogenous uric acid. Patent CN202210611537 reports a strain of lactobacillus plantarum L9 with high cholesterol lowering capacity; patent CN202110965484 reports lactobacillus acidophilus LA85 which can remarkably reduce the blood fat of mice. Patent CN202111476000 reports that lactobacillus reuteri MRD01 has functions of reducing weight and lowering blood sugar; patent CN202111573855 reports that lactobacillus rhamnosus HF01 can reduce the weight of obese mice induced by high fat diet.
In the prior art, probiotic formulations directed against glycemic control are commonly single probiotic strains, as well as formulations combined with prebiotics or extracts (patent CN202210161883, combination of lactobacillus paracasei LC-37 with dietary fibers). At present, a plurality of probiotic compound preparation products with different functions are lacked, and although a plurality of probiotic vermilions are compounded in some reports, a plurality of probiotic strains are simply added in the formulas, so that the simple superposition of functions is only carried out, and scientific researches on strain compounding are lacked (patent CN202111597046, 1:1:1:1 composite probiotic powder of 5 strains); or the added probiotics strains are all strains with the function of reducing blood sugar (patent CN202011004485, the complex of lactobacillus salivarius AP-32 with the function of reducing blood sugar and lactobacillus reuteri GL-104).
Patent 202110638090 discloses that the blood sugar reducing function of bacillus natto is superior to that of single bacillus natto, but the bacillus natto is not in the list of edible strains, and has safety risks. Patent 202110250523 discloses that after the combination of probiotic compounds (bifidobacterium longum, bifidobacterium lactis, lactobacillus acidophilus, clostridium butyricum and inactivated akkermansia muciniphila) with prebiotics (natto lyophilized powder and chicory powder), the hypoglycemic effect is superior to that of the probiotic compounds, but as such, clostridium butyricum in the formulation is not in the list of edible fungi, and there is a safety risk.
In summary, the prior art has limited effect of singly using the hypoglycemic probiotics, and the multi-strain composite preparation either lacks multifunctional synergy, or lacks scientific basis of strain combination or has safety risk of strain eating.
Disclosure of Invention
In order to solve the technical problems, the invention provides a probiotic composition and a probiotic prebiotic composite preparation with blood sugar reducing effect. Firstly, scientific researches show that after four strains are compounded, the strain proliferation and blood sugar reducing effect can be synergistically enhanced, and the blood sugar reducing effect can be remarkably enhanced. And each strain selected by the invention has no toxic or side effect, can be safely eaten, and does not have safety risk. Secondly, on the basis of the probiotic composition, the invention further compounds prebiotics (galacto-oligosaccharides and fructo-oligosaccharides), and the specific compound probiotic powder and prebiotic combination are adopted, and scientific researches prove that the formula components of the probiotic preparation fully exert synergistic effect, have better efficacy than the independent materials, and can further obviously strengthen the blood sugar reducing efficacy.
The specific technical scheme of the invention is as follows:
in a first aspect, the invention provides a probiotic composition with hypoglycemic effect, comprising bifidobacterium longum WHH2270, bifidobacterium animalis WHH2276, lactobacillus fermentum a, lactobacillus fermentum B.
The microorganism classification of bifidobacterium longum WHH2270 is named bifidobacterium longum subsp. Bifidobacterium longum subsp.longum; has been deposited at the microorganism strain collection of Guangdong province at 10.18 of 2022, with the deposit address of Hirschner No. 100 in Guangzhou City and the deposit number of GDMCC No:62900.
the microorganism classification of bifidobacterium animalis WHH2276 is designated as bifidobacterium animalis subsp. Bifidobacterium animalis subsp. Has been deposited at the microorganism strain collection of Guangdong province at 10.18 of 2022, with the deposit address of Hirschner No. 100 in Guangzhou City and the deposit number of GDMCC No:62901.
the lactobacillus fermentum A is lactobacillus fermentum WH 2644, and the microorganism classification is named as Limosilobacillus fermentum and is preserved in China general microbiological culture Collection center, with a preservation address: the preservation number of the Beijing city Chaoyang area North Chen Xili No.1 and 3 is CGMCC No.16754.
The lactobacillus fermentum B is lactobacillus fermentum WH3906, and the microorganism classification is named as Limosilobacillus fermentum and is preserved in China general microbiological culture Collection center, with a preservation address: no.1 and No. 3 of North Chen Xili No.1 in the Chaoyang area of Beijing city are preserved with the number of CGMCC No.19472.
The probiotic composition of the invention takes bifidobacterium longum WHH2270 with the blood sugar reducing effect as core bacteria, and then the other three bacteria are compounded around the strain. Wherein:
regarding bifidobacterium longum WHH2270, this strain has the following characteristics: (1) The bifidobacterium longum subspecies of the invention have the function of reducing blood sugar for animals with glucose-lipid disorder of insulin resistance, and can not influence normal blood sugar for healthy animals. Namely, the bifidobacterium longum subspecies longum has the effect of reducing blood sugar only for patients with hyperglycemia after being taken, does not have negative influence on blood sugar of normal people, and does not cause the occurrence of hypoglycemia. Therefore, the preparation method has no side effect and wider application field, and can be applied to not only the medicine field but also the food or health care product field and the like. (2) The bifidobacterium longum subspecies longum can regulate the disturbed intestinal flora and improve the abundance of beneficial bacteria in intestinal tracts. (3) The bifidobacterium longum subspecies longum disclosed by the invention can be used for improving the content of short-chain fatty acid in intestinal tracts, improving the content of acetic acid in serum, stimulating the expression of G protein coupled receptors of the intestinal tracts and pancreas-mediated short-chain fatty acid, and reducing blood sugar. (4) The bifidobacterium longum subspecies are derived from the feces of healthy infants, and the whole genome sequencing analysis shows that the strain has no toxic genes, has no toxic or side effects in animal evaluation, is sensitive to various antibiotics, and has certain advantages compared with the traditional medicines for treating glycolipid metabolic disorders at present.
Regarding the probiotic composition after the compounding according to the invention: interactions between probiotic strains are complex and may be manifested as mutual independence (functional superposition), mutual synergy, mutual competition or functional inhibition. In the multi-strain compound preparation with the blood sugar reducing effect reported in the prior art, the strains are mostly in function superposition, have weak mutual synergistic effect or have safety risk of eating by the strains. In vitro and animal experiments show that the bifidobacterium longum WHH2270 with the function of reducing blood sugar is compounded with other 3 functional strains (lactobacillus fermentum WHH2644 with the function of reducing uric acid, bifidobacterium animalis WHH2276 with the function of reducing blood fat and lactobacillus fermentum WHH3906 with the function of reducing weight), so that the simple functions different from the strains are overlapped, and the proliferation and blood sugar reducing effects of the compounded strains can be synergistically enhanced; through scientific researches, it is determined that the probiotic composition provided by the invention can fully play a synergistic effect between strains, and the blood sugar reducing effect is extremely remarkably enhanced. On the other hand, each strain selected by the invention has no toxic or side effect, can be safely eaten, and does not have safety risk.
Preferably, the bifidobacterium longum WHH2270, bifidobacterium animalis WHH2276, lactobacillus fermentum a and lactobacillus fermentum B are present in the form of a lyophilized powder.
Preferably, the bifidobacterium longum WH2270 freeze-dried powder is 10-15 parts by weight, the bifidobacterium animalis WH2276 freeze-dried powder is 1-4 parts by weight, the lactobacillus fermentum A freeze-dried powder is 10-15 parts by weight, and the lactobacillus fermentum B freeze-dried powder is 1-4 parts by weight.
In a second aspect, the invention provides a probiotic prebiotic composite preparation with blood glucose reducing effect, which comprises bifidobacterium longum WHH2270 freeze-dried powder, bifidobacterium animalis WHH2276 freeze-dried powder, lactobacillus fermentum A freeze-dried powder, lactobacillus fermentum B freeze-dried powder, fructo-oligosaccharide and galacto-oligosaccharide.
Based on the probiotic composition, the invention further compounds prebiotics, namely galacto-oligosaccharides and fructo-oligosaccharides, and scientific researches prove that the formula components of the probiotic preparation provided by the invention fully exert synergistic effect, have better effects than the independent materials, and can further obviously strengthen the blood sugar reducing effect.
Preferably, the bifidobacterium longum WH2270 freeze-dried powder is 10-15 parts by weight, the bifidobacterium animalis WH2276 freeze-dried powder is 1-4 parts by weight, the lactobacillus fermentum A freeze-dried powder is 10-15 parts by weight, the lactobacillus fermentum B freeze-dried powder is 1-4 parts by weight, the fructo-oligosaccharide is 10-20 parts by weight, and the galacto-oligosaccharide is 50-55 parts by weight.
In a third aspect, the invention provides the use of a probiotic composition or a probiotic prebiotic composite formulation as described above in the preparation of a product having a prophylactic and/or therapeutic effect on diabetes.
Preferably, the product is a tablet, capsule, powder, pill, granule or solution.
Preferably, the product is a pharmaceutical.
Preferably, the medicament further comprises pharmaceutically acceptable auxiliary materials.
Compared with the prior art, the invention has the beneficial effects that:
(1) According to scientific researches, the invention discovers that after four specific strains (bifidobacterium longum WHH2270, bifidobacterium animalis WHH2276, lactobacillus fermentum WHH2644 and lactobacillus fermentum WHH 3906) are compounded, the proliferation and blood sugar reducing effects of the strains can be synergistically enhanced, and the blood sugar reducing effect is extremely obviously enhanced. On the other hand, each strain selected by the invention has no toxic or side effect, can be safely eaten, and does not have safety risk.
(2) Based on the probiotic composition, the invention further compounds prebiotics, namely galacto-oligosaccharides and fructo-oligosaccharides, adopts the specific compound probiotic powder and prebiotic combination, and has the formula components of the probiotic preparation fully playing synergistic effect through scientific researches, thereby having better efficacy than the independent materials and extremely remarkably strengthening the blood sugar reducing efficacy.
Drawings
FIG. 1 culture media OD of combination culture of different strains 600 And (5) a value graph.
Detailed Description
The invention is further described below with reference to examples.
General examples
A probiotic composition with blood sugar lowering effect comprises Bifidobacterium longum WH2270 lyophilized powder, bifidobacterium animalis WH2276 lyophilized powder, lactobacillus fermentum WH2644 lyophilized powder, and Lactobacillus fermentum WH3906 lyophilized powder.
Preferably, the bifidobacterium longum WH2270 freeze-dried powder is 10-15 parts by weight, the bifidobacterium animalis WH2276 freeze-dried powder is 1-4 parts by weight, the lactobacillus fermentum A freeze-dried powder is 10-15 parts by weight, and the lactobacillus fermentum B freeze-dried powder is 1-4 parts by weight.
The microorganism classification of bifidobacterium longum WHH2270 is named bifidobacterium longum subsp. Bifidobacterium longum subsp.longum; has been deposited at the microorganism strain collection of Guangdong province at 10.18 of 2022, with the deposit address of Hirschner No. 100 in Guangzhou City and the deposit number of GDMCC No:62900.
the microorganism classification of bifidobacterium animalis WHH2276 is designated as bifidobacterium animalis subsp. Bifidobacterium animalis subsp. Has been deposited at the microorganism strain collection of Guangdong province at 10.18 of 2022, with the deposit address of Hirschner No. 100 in Guangzhou City and the deposit number of GDMCC No:62901.
the lactobacillus fermentum A is lactobacillus fermentum WH 2644, the microorganism classification is Limosilactobacillus fermentum, and the lactobacillus fermentum A is preserved in China general microbiological culture Collection center of China Committee for culture Collection of microorganisms, and the preservation address is: the preservation number of the Beijing city Chaoyang area North Chenxi way No.1 and No. 3 is CGMCC No.16754;
the lactobacillus fermentum B is lactobacillus fermentum WH3906, the microorganism classification is Limosilactobacillus fermentum, and the lactobacillus fermentum B is preserved in China general microbiological culture Collection center (China general microbiological culture Collection center) for 3 and 13 days in 2020, and the preservation address is: no.1 and No. 3 of North Chen Xili No.1 in the Chaoyang area of Beijing city are preserved with the number of CGMCC No.19472.
A probiotic prebiotic compound preparation with blood sugar lowering effect comprises Bifidobacterium longum WH2270 lyophilized powder, bifidobacterium animalis WH2276 lyophilized powder, lactobacillus fermentum WH2644 lyophilized powder, lactobacillus fermentum WH3906 lyophilized powder, fructo-oligosaccharide and galacto-oligosaccharide.
The bifidobacterium longum WH2270 freeze-dried powder comprises, by weight, 10-15 parts of bifidobacterium longum WH2270 freeze-dried powder, 1-4 parts of bifidobacterium animalis WH2276 freeze-dried powder, 10-15 parts of lactobacillus fermentum A freeze-dried powder, 1-4 parts of lactobacillus fermentum B freeze-dried powder, 10-20 parts of fructo-oligosaccharides and 50-55 parts of galacto-oligosaccharides. A product containing the probiotic composition or probiotic prebiotic composite preparation and having the effect of preventing and/or treating diabetes is provided.
Preferably, the product is a tablet, capsule, powder, pill, granule or solution. The product is a medicament. Further preferably, the medicament further comprises pharmaceutically acceptable excipients.
Specific examples the following examples relate to the following methods of preparation of the culture medium:
MRS-Cys Medium (1L): 10g of peptone, 5g of yeast extract powder, 20g of glucose, 10g of beef extract and K HPO 2 42g, diammonium citrate 2g, mgSO 2 -7HO 2 0.58g，MnSO 2 -4HO 2 0.25g of anhydrous sodium acetate 5g, 1mL of Tween 80, 0.5g of cysteine hydrochloride, distilled water to a volume of 1L, adjusting the pH to 6.5, and sterilizing at 121 ℃ for 15min.
The culture medium is selected as a basic culture medium, and is used as a blank control group, and the experimental group replaces glucose with prebiotics on the basis of the basic culture medium.
Example 1 in vitro study of combinations of strains
The interaction between the probiotic strains is complex and may appear to be synergistic, functional stack; competing with each other, inhibiting function; or may be independent of each other. The interaction among different strains can be clearly deconstructed, and a basis can be provided for the combination of the strains in the formula.
4 strains with functions of losing weight, reducing blood fat, reducing blood sugar and reducing blood uric acid respectively are tested by utilizing an in vitro co-culture system to test the growth interaction among the functional strains, so that the optimal combination of the functional strains is obtained.
(1) 4 probiotics (Lactobacillus fermentum WH3906, bifidobacterium animalis WH2276, bifidobacterium longum WH2270, and Lactobacillus fermentum WH2644) were inoculated into 10ml of MRS-Cys medium at an inoculum size of 2%, and cultured in anaerobic bags at 37deg.C for 14 hr.
(2) According to different combinations, 4 strains are inoculated in equal proportion, the total inoculum size is 2 percent, and the strains are inoculated into 10ml of culture medium and are subjected to anaerobic culture for 14 hours at 37 ℃. Taking each culture solution, detecting OD of the culture solution 600 Values.
(3) The detection data show (figure 1), WHH2270 and another 3 strains were mixed and cultured in pairs, and the OD of the culture solution was measured 600 The values were all greater than the culture broth of the single strain, indicating that WHH2270 had growth synergy with the other 3 probiotics. Further, the mixed culture solution of WHH2270, WHH2644 and WHH3906 and OD 600 More than three strains of bacteria are cultured independently. Further, the mixed culture solution of WHH2270 and four strains WHH2644, WHH3906 and WHH2276, OD 600 More than three strains of bacteria mixed culture solution. The results show that the 4 probiotics in the test, when combined together, have no competitive inhibition, but have the effect of growth synergy.
Example 2 in vitro study of Strain combinations and prebiotic formulations
The prebiotics are used as proliferation factors of probiotics and have a synergistic effect on the proliferation of the probiotics. By adding various prebiotics into the culture medium, comparing the proliferation conditions of the strain after culture, the optimal prebiotics and the combination proportion of the prebiotics are screened out.
(1) 8 common prebiotic raw materials including xylo-oligosaccharide, fructo-oligosaccharide, galacto-oligosaccharide, arabinoxylan, resistant dextrin, inulin, polydextrose and chitosan oligosaccharide are selected as single carbon source to replace glucose in MRS-Cys culture medium, and are sterilized at 121deg.C for 15min.
(2) The 4 strains were inoculated into 10ml of the above medium at an inoculum size of 2%, and cultured in an anaerobic bag at 37℃for 14 hours.
(3) Taking each culture solution, detecting OD 600 。
MRS-Cys culture medium is used as blank control, OD 600 The results are shown in Table 1. The data show that growth of WHH2644 prefers fructooligosaccharides, growth of WHH3906 prefers xylo-and fructooligosaccharides, and growth of WHH2270 and WHH2276 prefers galactooligosaccharides. Fructo-oligosaccharides and galacto-oligosaccharides are widely used as prebiotic combinations in food products, especially infant food products. Further, the ratio of fructo-oligosaccharide to galacto-oligosaccharide was investigated and the results are shown in Table 2. The data show that fructo-and galacto-oligosaccharides are present at 1:6, optimal for growth of the probiotic combinations of the present invention.
TABLE 1 culture media OD of different prebiotic Medium for growth of probiotic strains 600 Value of
TABLE 2 culture media OD of different fructo-and galacto-oligosaccharide ratio Medium for Combined growth of probiotics 600 Value of
Example 3: bifidobacterium longum WHH2270 formulations
Live bifidobacterium longum WHH2270 formulationThe bacterial count is 5 multiplied by 10 10 cfu/g, comprising the following components: bifidobacterium longum WHH2270 lyophilized powder and maltodextrin. Wherein the mass percentage of the bifidobacterium longum WH2270 freeze-dried powder is 50 percent, and the mass percentage of the maltodextrin is 50 percent.
The preparation method of the bifidobacterium longum WHH2270 preparation comprises the following steps:
(1) Preparation of bifidobacterium longum WHH2270 lyophilized powder:
(1.1) Strain activation: taking a bifidobacterium longum WH2270 freezing tube, inoculating 2% of the inoculating amount into a liquid MRS-Cys culture medium, and performing anaerobic culture at 37 ℃ overnight to obtain a generation-1 activated seed liquid;
(1.2) spread cultivation: inoculating the 1 generation of activated seed liquid with 2% inoculum size into a liquid MRS-Cys culture medium, and performing anaerobic culture at 37 ℃ overnight to obtain 2 generation of activated seed liquid;
(1.3) fermentation: inoculating 2 generation of activated seed solution with 5% inoculum size into MRS-Cys culture medium, controlling pH to 5.5, 37 deg.C, introducing CO 2 Culturing in a fermentation tank for 16h to obtain a fermented product;
(1.4) bacterial sludge collection and emulsification: placing the fermented product at 8000rpm, centrifuging for 10min, discarding supernatant, collecting bacterial mud, and mixing the bacterial mud with the mass ratio of 1:1, adding bacterial mud into a freeze-drying protective agent, and emulsifying for 15min at 180rpm to obtain emulsion; the preparation of the lyoprotectant is as follows: uniformly mixing 1.3wt% of glycerin, 24.2wt% of skim milk powder, 1.0wt% of sodium glutamate, 16.1wt% of lactose and the balance of deionized water, and sterilizing at 105 ℃ for 10 min;
(1.5) freeze-drying and crushing: freezing the emulsion at-80deg.C, drying at-50deg.C under vacuum degree of 0.2mbar, sieving with 20 mesh sieve to obtain lyophilized powder of Bifidobacterium longum WHH2270 with viable count of 1×10 11 cfu/g。
(2) And weighing maltodextrin and bifidobacterium longum WHH2270 freeze-dried powder, and uniformly mixing the maltodextrin and the bifidobacterium longum WHH2270 freeze-dried powder to prepare powder.
Example 4: bifidobacterium animalis WHH2276 preparation
The viable count of the preparation of the bifidobacterium animalis WHH2276 is 5 multiplied by 10 10 cfu/g, comprising the following components: bifidobacterium animalis WH2276 freeze-dried powder and wheatAnd (3) maltodextrin. Wherein the mass percentage of the bifidobacterium animalis WH2276 freeze-dried powder is 10 percent, and the mass percentage of maltodextrin is 90 percent.
The preparation method of the bifidobacterium animalis WHH2276 preparation comprises the following steps:
(1) Preparation of bifidobacterium animalis WHH2276 lyophilized powder:
(1.1) Strain activation: taking a bifidobacterium animalis WH2276 freezing tube, inoculating 2% of the inoculating amount into a liquid MRS-Cys culture medium, and performing anaerobic culture at 37 ℃ for overnight to obtain a generation-1 activated seed liquid;
(1.2) spread cultivation: inoculating the 1 generation of activated seed liquid with 2% inoculum size into a liquid MRS-Cys culture medium, and performing anaerobic culture at 37 ℃ overnight to obtain 2 generation of activated seed liquid;
(1.3) fermentation: inoculating 2 generation of activated seed solution with 5% inoculum size into MRS-Cys culture medium, controlling pH to 5.5, 37 deg.C, introducing CO 2 Culturing in a fermentation tank for 16h to obtain a fermented product;
(1.4) bacterial sludge collection and emulsification: placing the fermented product at 8000rpm, centrifuging for 10min, discarding supernatant, collecting bacterial mud, and mixing the bacterial mud with the mass ratio of 1:1, adding bacterial mud into a freeze-drying protective agent, and emulsifying for 15min at 180rpm to obtain emulsion; the preparation of the lyoprotectant is as follows: uniformly mixing 1.3wt% of glycerin, 24.2wt% of skim milk powder, 1.0wt% of sodium glutamate, 16.1wt% of lactose and the balance of deionized water, and sterilizing at 105 ℃ for 10 min;
(1.5) freeze-drying and crushing: freezing the emulsion at-80deg.C, drying at-50deg.C under vacuum degree of 0.2mbar, sieving with 20 mesh sieve to obtain lyophilized powder of animal bifidobacterium WH2276 with viable count of 5×10 11 cfu/g。
(2) And weighing maltodextrin and bifidobacterium animalis WH2276 freeze-dried powder, and uniformly mixing the maltodextrin and the bifidobacterium animalis WH2276 freeze-dried powder to prepare powder.
Example 5: lactobacillus fermentum WH2644 preparation
The viable count of the lactobacillus fermentum WH2644 preparation is 5×10 10 cfu/g, comprising the following components: lactobacillus fermentum WHH2644 lyophilized powder and maltodextrin. Wherein the mass percentage of the lactobacillus fermentum WH2644 freeze-dried powder is 50 percent, and the weight percentage of the lactobacillus fermentum WH2644 freeze-dried powder is wheatThe mass percentage of the maltodextrin is 50%.
The preparation method of the lactobacillus fermentum WH2644 preparation comprises the following steps:
(1) Preparation of lactobacillus fermentum WHH2644 lyophilized powder:
(1.1) Strain activation: inoculating lactobacillus fermentum WH2644 cryopreservation tube with 2% inoculum size into liquid MRS culture medium, and culturing at 37deg.C overnight to obtain 1 generation activated seed solution;
(1.2) spread cultivation: inoculating the 1-generation activated seed liquid with 2% inoculum size in a liquid MRS culture medium, and culturing overnight at 37 ℃ to obtain a 2-generation activated seed liquid;
(1.3) fermentation: inoculating 2 generation of activated seed solution with 5% inoculum size into MRS culture medium, controlling pH to 5.5, and introducing N at 37deg.C 2 Culturing for 16h overnight to obtain fermented product;
(1.4) bacterial sludge collection and emulsification: placing the fermented product at 8000rpm, centrifuging for 10min, discarding supernatant, collecting bacterial mud, and mixing the bacterial mud with the mass ratio of 1:1, adding bacterial mud into a freeze-drying protective agent, and emulsifying for 30min at 200rpm to obtain emulsion; the preparation of the lyoprotectant is as follows: uniformly mixing 1.3wt% of glycerin, 24.2wt% of skim milk powder, 1.0wt% of sodium glutamate, 16.1wt% of lactose and the balance of deionized water, and sterilizing at 105 ℃ for 10 min;
(1.5) freeze-drying and crushing: freezing the emulsion at-80deg.C, drying at-50deg.C under vacuum degree of 0.2mbar, sieving with 20 mesh sieve to obtain lyophilized powder of Lactobacillus fermentum WHH2644 with viable count of 1×10 11 cfu/g。
(2) And weighing maltodextrin and lactobacillus fermentum WH2644 freeze-dried powder, and uniformly mixing the maltodextrin and the lactobacillus fermentum WH2644 freeze-dried powder to prepare powder.
Example 6: lactobacillus fermentum WH3906 preparation
The viable count of the lactobacillus fermentum WHH3906 preparation is 5×10 10 cfu/g, comprising the following components: lactobacillus fermentum WHH3906 lyophilized powder and maltodextrin. Wherein the mass percentage of the lactobacillus fermentum WH3906 freeze-dried powder is 10 percent, and the mass percentage of the maltodextrin is 90 percent.
The preparation method of the lactobacillus fermentum WH3906 preparation comprises the following steps:
(1) Preparation of lactobacillus fermentum WHH3906 lyophilized powder:
(1.1) Strain activation: inoculating lactobacillus fermentum WH3906 in a freezing tube with an inoculum size of 2% in a liquid MRS culture medium, and culturing overnight at 37 ℃ to obtain 1 generation of activated seed liquid;
(1.2) spread cultivation: inoculating the 1-generation activated seed liquid with 2% inoculum size in a liquid MRS culture medium, and culturing overnight at 37 ℃ to obtain a 2-generation activated seed liquid;
(1.3) fermentation: inoculating 2 generation of activated seed solution with 5% inoculum size into MRS culture medium, controlling pH to 5.5, and introducing N at 37deg.C 2 Culturing for 16h overnight to obtain fermented product;
(1.4) bacterial sludge collection and emulsification: placing the fermented product at 8000rpm, centrifuging for 10min, discarding supernatant, collecting bacterial mud, and mixing the bacterial mud with the mass ratio of 1:1, adding bacterial mud into a freeze-drying protective agent, and emulsifying for 30min at 200rpm to obtain emulsion A; the preparation of the lyoprotectant is as follows: uniformly mixing 1.3wt% of glycerin, 24.2wt% of skim milk powder, 1.0wt% of sodium glutamate, 16.1wt% of lactose and the balance of deionized water, and sterilizing at 105 ℃ for 10 min;
(1.5) freeze-drying and crushing: freezing the emulsion at-80deg.C, drying at-50deg.C under vacuum degree of 0.2mbar, sieving with 20 mesh sieve to obtain lyophilized powder of Lactobacillus fermentum WHH3906 with viable count of 5×10 11 cfu/g。
(2) And weighing maltodextrin and lactobacillus fermentum WH3906 freeze-dried powder, and uniformly mixing the maltodextrin and the lactobacillus fermentum WH3906 freeze-dried powder to prepare powder.
Example 7: probiotic composition formulation A
Probiotic composition preparation A with viable count of 5×10 10 cfu/g, consisting of the following components: bifidobacterium longum WH2270 freeze-dried powder, bifidobacterium animalis WH2276 freeze-dried powder, lactobacillus fermentum WH2644 freeze-dried powder, lactobacillus fermentum WH3906 freeze-dried powder and maltodextrin. Wherein the mass percentage of the bifidobacterium longum WHH2270 freeze-dried powder is 12.5 percent, the mass percentage of the bifidobacterium animalis WHH2276 freeze-dried powder is 2.5 percent, the mass percentage of the lactobacillus fermentum WHH2644 freeze-dried powder is 12.5 percent, and the lactobacillus fermentum WHH3906 freeze-dried powderThe mass percentage of the powder is 2.5 percent, and the mass percentage of maltodextrin is 70 percent.
The preparation method of the probiotic composition preparation A comprises the following steps:
(1) Maltodextrin and bifidobacterium longum WHH2270 freeze-dried powder, bifidobacterium animalis WHH2276 freeze-dried powder, lactobacillus fermentum WHH2644 freeze-dried powder and lactobacillus fermentum wh 3906 freeze-dried powder are weighed.
Wherein, the preparation method of the bifidobacterium longum WHH2270 freeze-dried powder is the same as that of example 3, the preparation method of the bifidobacterium animalis WHH2276 freeze-dried powder is the same as that of example 4, the preparation method of the lactobacillus fermentum WHH2644 freeze-dried powder is the same as that of example 5, the preparation method of the lactobacillus fermentum WH3906 freeze-dried powder is the same as that of example 6, and the viable count of the bifidobacterium longum WHH2270 freeze-dried powder is 1 multiplied by 10 11 cfu/g, viable count of bifidobacterium animalis WHH2276 freeze-dried powder is 5 multiplied by 10 11 cfu/g, viable count of Lactobacillus fermentum WH2644 lyophilized powder 1×10 11 cfu/g, viable count of lactobacillus fermentum WHH3906 freeze-dried powder is 5 multiplied by 10 11 cfu/g。
(2) And uniformly mixing maltodextrin with the 4 probiotics freeze-dried powders, and preparing powder.
Example 8: probiotic and prebiotic composite preparation
Probiotic and prebiotic composite preparation with viable count of 5×10 10 cfu/g, consisting of the following components: the preparation method comprises the steps of bifidobacterium longum WH2270 freeze-dried powder, bifidobacterium animalis WH2276 freeze-dried powder, lactobacillus fermentum WH2644 freeze-dried powder, lactobacillus fermentum WH3906 freeze-dried powder, fructo-oligosaccharide and galacto-oligosaccharide. Wherein the mass percentage of the bifidobacterium longum WH2270 freeze-dried powder is 12.5%, the mass percentage of the bifidobacterium animalis WH2276 freeze-dried powder is 2.5%, the mass percentage of the lactobacillus fermentum WH2644 freeze-dried powder is 12.5%, the mass percentage of the lactobacillus fermentum WH3906 freeze-dried powder is 2.5%, the mass percentage of the fructo-oligosaccharide is 17.5%, and the mass percentage of the galacto-oligosaccharide is 52.5%.
The preparation method of the probiotic prebiotic composite preparation comprises the following steps:
(1) Weighing fructo-oligosaccharide, galacto-oligosaccharide and bifidobacterium longum WH2270 freeze-dried powder, bifidobacterium animalis WH2276 freeze-dried powder, lactobacillus fermentum WH2644 freeze-dried powder and lactobacillus fermentum WH3906 freeze-dried powder.
The preparation method of the bifidobacterium longum WHH2270 freeze-dried powder is the same as that of example 3. The preparation method of bifidobacterium animalis WH2276 freeze-dried powder is the same as in example 4. The preparation method of the lactobacillus fermentum WHH2644 freeze-dried powder is the same as that of example 5. The preparation method of the lactobacillus fermentum WH3906 freeze-dried powder is the same as that of example 6. Viable count of bifidobacterium longum WHH2270 freeze-dried powder is 1 multiplied by 10 11 cfu/g, viable count of bifidobacterium animalis WHH2276 freeze-dried powder is 5 multiplied by 10 11 cfu/g, viable count of Lactobacillus fermentum WH2644 lyophilized powder 1×10 11 cfu/g, viable count of lactobacillus fermentum WHH3906 freeze-dried powder is 5 multiplied by 10 11 cfu/g。
(2) Mixing fructo-oligosaccharide, galacto-oligosaccharide and the 4 probiotics freeze-dried powder uniformly, and preparing into powder.
Comparative example 1: probiotic composition formulation B
Probiotic composition preparation B with viable count of 5×10 10 cfu/g, differing from example 7 in the replacement of bifidobacterium longum WHH2270 with other commercial bifidobacterium longum, consisting of the following components: commercial bifidobacterium longum freeze-dried powder, bifidobacterium animalis WH2276 freeze-dried powder, lactobacillus fermentum WH2644 freeze-dried powder, lactobacillus fermentum WH3906 freeze-dried powder and maltodextrin.
The preparation of the probiotic composition formulation B was the same as in example 7.
Comparative example 2: probiotic composition formulation C
Probiotic composition preparation C with viable count of 5×10 10 cfu/g, differing from example 7 in the replacement of bifidobacterium animalis WHH2276 with other commercial bifidobacterium animalis, consisting of the following components: bifidobacterium longum WH2270 freeze-dried powder, commercial bifidobacterium freeze-dried powder, lactobacillus fermentum WH2644 freeze-dried powder, lactobacillus fermentum WH3906 freeze-dried powder and maltodextrin.
The preparation of the probiotic composition formulation C was the same as in example 7.
Comparative example 3: probiotic composition formulation D
Probiotic composition preparation D with viable count of 5×10 10 cfu/g, differs from example 7 in that other commercial Lactobacillus fermentum was used insteadLactobacillus fermentum WHH2644, consisting of the following components: bifidobacterium longum WHH2270 freeze-dried powder, bifidobacterium animalis WHH2276 freeze-dried powder, commercial lactobacillus fermentum freeze-dried powder, lactobacillus fermentum WHH3906 freeze-dried powder and maltodextrin.
The probiotic composition formulation D was prepared in the same manner as in example 7.
Comparative example 4: probiotic composition formulation E
Probiotic composition formulation E with viable count of 5×10 10 cfu/g, differing from example 7 in the replacement of lactobacillus fermentum WHH3906 with other commercial lactobacillus fermentum, consisting of the following components: bifidobacterium longum WHH2270 freeze-dried powder, bifidobacterium animalis WHH2276 freeze-dried powder, lactobacillus fermentum WHH2644 freeze-dried powder, commercial lactobacillus fermentum freeze-dried powder and maltodextrin.
The preparation of the probiotic composition formulation E was the same as in example 7.
Example 9: evaluation of hypoglycemic efficacy of formulations
The 5dpf wild type AB strain zebra fish was selected and divided into 13 groups: example 3 experimental group, example 4 experimental group, example 5 experimental group, example 6 experimental group, example 7 experimental group, example 8 experimental group, comparative example 1 experimental group, comparative example 2 experimental group, comparative example 3 experimental group, comparative example 4 experimental group, positive control pioglitazone hydrochloride 20.0 μg/mL, and a normal control group and a model control group were simultaneously set, each group of 30 zebra fish.
The samples were each given water-soluble at a concentration of 2mg/ml. Except for the normal control group, the rest experimental groups are water-soluble in the daytime and are given high-fat feed (yolk powder) and water-soluble in the evening and are given high sugar (glucose), so that a zebra fish high-sugar high-fat model is established. The samples were treated with high-fat feed for 15 hours (7.5 hours per day), glucose for 33 hours (16.5 hours per day), and at 28℃for 48 hours, and the blood glucose level in the zebra fish was analyzed by collecting data using a blood glucose meter, and the blood glucose-lowering effect of the samples was evaluated by the statistical analysis result of the index. Statistical treatment results are expressed in mean+ -SE. Statistical analysis was performed with SPSS26.0 software, p <0.05 indicated that the differences were statistically significant.
The results of the experiments are shown in table 3, and the hypoglycemic effect of the probiotic composition preparation of example 7 is significantly better than that of the single strain preparation (examples 3-6), which shows that after the bifidobacterium longum WHH2270 is compounded with other three strains, the hypoglycemic capability of the bifidobacterium longum WHH2270 can be further enhanced, and the data of example 7 is compared with the data of comparative examples 1-4, and the data of example 7 is optimal, and the reason for analysis is that:
the replacement of bifidobacterium longum WHH2270 with other commercial bifidobacterium longum in comparative example 1 demonstrated that the other commercial bifidobacterium longum was not as effective as the bifidobacterium longum WHH2270 of the present invention.
Comparative examples 2-4 replacement of lactobacillus fermentum WHH2644 and lactobacillus fermentum WHH3906 with other commercial bifidobacterium animalis, commercial lactobacillus fermentum, respectively, resulted in less hypoglycemic capacity than example 7, demonstrating that only the four specific strains of the invention were optimal after compounding.
Example 7 the hypoglycemic ability of example 7 is inferior to example 8, demonstrating that the introduction of prebiotics can have a synergistic effect with the combination of strains, further enhancing the hypoglycemic ability of the strains.
TABLE 3 blood sugar measurement results for each group of zebra fish
| Group of | Blood glucose level of zebra fish (mmol/L) |
| Normal control group | 0.90±0.039 *** |
| Model control group | 3.31±0.134 |
| Pioglitazone hydrochloride | 2.62±0.090 *** |
| Example 3 (bifidobacterium longum WHH 2270) | 2.78±0.138 ** |
| Example 4 (bifidobacterium animalis WHH 2276) | 3.14±0.237 |
| Example 5 (Lactobacillus fermentum WH2644) | 2.88±0.114 ** |
| Example 6 (Lactobacillus fermentum WH3906) | 2.99±0.099 |
| Example 7 (probiotic composition formulation A) | 1.97±0.104 *** |
| Example 8 (Probiotics prebiotics Complex formulation) | 1.73±0.068 *** |
| Comparative example 1 (probiotic composition formulation B, replacement of WHH2270 with commercial bifidobacterium longum) | 2.43±0.189 *** |
| Comparative example 2 (probiotic composition formulation C, replacement of WHH2276 with bifidobacterium in a commercial animal) | 2.31±0.177 *** |
| Comparative example 3 (probiotic composition formulation D, substitution of WHH2644 with commercial lactobacillus fermentum) | 2.35±0.183 *** |
| Comparative example 4 (probiotic composition formulation E, substitution of commercial Lactobacillus fermentum for WH 3906) | 2.29±0.161 *** |
In comparison with the control group of the model, * p<0.05， ** p<0.01， *** p<0.001。
the raw materials and equipment used in the invention are common raw materials and equipment in the field unless specified otherwise; the methods used in the present invention are conventional in the art unless otherwise specified.
The foregoing description is only a preferred embodiment of the present invention, and is not intended to limit the present invention, and any simple modification, variation and equivalent transformation of the above embodiment according to the technical substance of the present invention still fall within the scope of the technical solution of the present invention.
Claims (10)
1. A probiotic composition with hypoglycemic effect, characterized in that: comprises bifidobacterium longum WH2270, bifidobacterium animalis WH2276, lactobacillus fermentum A and lactobacillus fermentum B;
the microorganism classification of the bifidobacterium longum WHH2270 is named bifidobacterium longum subspecies longumBifidobacterium longum subsp. LongumThe method comprises the steps of carrying out a first treatment on the surface of the Has been deposited at the microorganism strain collection of Guangdong province at 10.18 of 2022, with the deposit address of Hirschner No. 100 in Guangzhou City and the deposit number of GDMCC No:62900;
the microorganism classification of the bifidobacterium animalis WHH2276 is named as bifidobacterium animalis subspecies lactisBifidobacterium animalis subsp. lactisThe method comprises the steps of carrying out a first treatment on the surface of the Has been deposited at the microorganism strain collection of Guangdong province at 10.18 of 2022, with the deposit address of Hirschner No. 100 in Guangzhou City and the deposit number of GDMCC No:62901.
2. the probiotic composition according to claim 1, characterized in that:
the saidLactobacillus fermentum A is Lactobacillus fermentum WH2644, and the microorganism classification is namedLimosilactobacillus fermentumThe strain has been deposited in China general microbiological culture Collection center, with a deposit address: the preservation number of the Beijing city Chaoyang area North Chenxi way No.1 and No. 3 is CGMCC No.16754;
the lactobacillus fermentum B is lactobacillus fermentum WH3906, and the microorganism classification is named asLimosilactobacillus fermentumThe strain is preserved in China general microbiological culture Collection center (China Committee for culture Collection), and the preservation address is as follows: no.1 and No. 3 of North Chen Xili No.1 in the Chaoyang area of Beijing city are preserved with the number of CGMCC No.19472.
3. A probiotic composition according to claim 1 or 2, characterized in that: the bifidobacterium longum WH2270, the bifidobacterium animalis WH2276, the lactobacillus fermentum A and the lactobacillus fermentum B exist in the form of freeze-dried powder.
4. A probiotic composition according to claim 3, characterized in that: the bifidobacterium longum WH2270 freeze-dried powder is 10-15 parts by weight, the bifidobacterium animalis WH2276 freeze-dried powder is 1-4 parts by weight, the lactobacillus fermentum A freeze-dried powder is 10-15 parts by weight and the lactobacillus fermentum B freeze-dried powder is 1-4 parts by weight.
5. A probiotic and prebiotic composite preparation with blood glucose reducing effect, which is characterized in that: comprises bifidobacterium longum WH2270 freeze-dried powder, bifidobacterium animalis WH2276 freeze-dried powder, lactobacillus fermentum A freeze-dried powder, lactobacillus fermentum B freeze-dried powder, fructo-oligosaccharide and galacto-oligosaccharide;
the microorganism classification of the bifidobacterium longum WHH2270 is named bifidobacterium longum subspecies longumBifidobacterium longum subsp. LongumThe method comprises the steps of carrying out a first treatment on the surface of the Has been deposited at the microorganism strain collection of Guangdong province at 10.18 of 2022, with the deposit address of Hirschner No. 100 in Guangzhou City and the deposit number of GDMCC No:62900;
the microorganism classification of the bifidobacterium animalis WHH2276 is named as bifidobacterium animalis subspecies lactisBifidobacterium animalis subsp. lactisThe method comprises the steps of carrying out a first treatment on the surface of the Has been deposited at the microorganism strain collection of Guangdong province at 10.18 of 2022, with the deposit address of Hirschner No. 100 in Guangzhou City and the deposit number of GDMCC No:62901.
6. the probiotic prebiotic composite formulation of claim 1 wherein:
the lactobacillus fermentum A is lactobacillus fermentum WH2644, and the microorganism classification is named asLimosilactobacillus fermentumThe strain has been deposited in China general microbiological culture Collection center, with a deposit address: the preservation number of the Beijing city Chaoyang area North Chenxi way No.1 and No. 3 is CGMCC No.16754;
the lactobacillus fermentum B is lactobacillus fermentum WH3906, and the microorganism classification is named asLimosilactobacillus fermentumThe strain is preserved in China general microbiological culture Collection center (China Committee for culture Collection), and the preservation address is as follows: no.1 and No. 3 of North Chen Xili No.1 in the Chaoyang area of Beijing city are preserved with the number of CGMCC No.19472.
7. The probiotic prebiotic composite formulation of claim 6 wherein: the bifidobacterium longum WH2270 freeze-dried powder comprises, by weight, 10-15 parts of bifidobacterium longum WH2270 freeze-dried powder, 1-4 parts of bifidobacterium animalis WH2276 freeze-dried powder, 10-15 parts of lactobacillus fermentum A freeze-dried powder, 1-4 parts of lactobacillus fermentum B freeze-dried powder, 10-20 parts of fructo-oligosaccharides and 50-55 parts of galacto-oligosaccharides.
8. Use of a probiotic composition according to one of claims 1 to 4 or a probiotic prebiotic composite formulation according to one of claims 5 to 7 for the preparation of a product having a prophylactic and/or therapeutic effect on diabetes.
9. The use according to claim 8, wherein: the product is tablet, capsule, powder, pill, granule or solution.
10. The use according to claim 8 or 9, wherein: the product is a medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211561125.2A CN116891810A (en) | 2022-12-15 | 2022-12-15 | Probiotic composition with blood sugar reducing effect and probiotic prebiotic composite preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211561125.2A CN116891810A (en) | 2022-12-15 | 2022-12-15 | Probiotic composition with blood sugar reducing effect and probiotic prebiotic composite preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116891810A true CN116891810A (en) | 2023-10-17 |
Family
ID=88309496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211561125.2A Pending CN116891810A (en) | 2022-12-15 | 2022-12-15 | Probiotic composition with blood sugar reducing effect and probiotic prebiotic composite preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116891810A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118028190A (en) * | 2024-04-15 | 2024-05-14 | 通化承诚药业有限公司 | Lactobacillus mucilaginosus BAS313 and application thereof in preparation of hypoglycemic products |
| CN118207140A (en) * | 2024-05-20 | 2024-06-18 | 微康益生菌(苏州)股份有限公司 | Akkermansia muciniphila Akk11 with blood sugar and blood lipid regulating effect and application thereof |
-
2022
- 2022-12-15 CN CN202211561125.2A patent/CN116891810A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118028190A (en) * | 2024-04-15 | 2024-05-14 | 通化承诚药业有限公司 | Lactobacillus mucilaginosus BAS313 and application thereof in preparation of hypoglycemic products |
| CN118207140A (en) * | 2024-05-20 | 2024-06-18 | 微康益生菌(苏州)股份有限公司 | Akkermansia muciniphila Akk11 with blood sugar and blood lipid regulating effect and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108208853B (en) | A kind of anti-alcoholic and liver-protecting probiotic oligopeptide compound preparation and preparation method | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| JP7590587B2 (en) | Composition for promoting bowel movement and use thereof | |
| CN108991327A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| CN112056399A (en) | Probiotic composition for enhancing immunity and application thereof | |
| TW202308670A (en) | Anti-aging composition using combination therapy comprising lactobacillius sp. and oriental medicine | |
| CN116814501B (en) | Bifidobacterium longum subspecies capable of relieving obesity and application thereof | |
| CN117264829A (en) | Lactobacillus plantarum for preventing and treating hypercholesterolemia, fermented product and application thereof | |
| CN108850397A (en) | A kind of probiotic gel candy and preparation method thereof of only diarrhea | |
| CN119177198B (en) | A herba Pentaenix for regulating and improving diarrhea, constipation and irritable bowel syndrome | |
| CN106176833A (en) | A kind of prevent and treat diabetes the compound probiotic liquid controlling body weight and preparation method thereof | |
| CN116445356A (en) | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof | |
| US10350248B2 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
| CN112029676B (en) | Probiotic composition beneficial to improving immunity and application thereof | |
| CN115838675A (en) | Lactobacillus rhamnosus and composition and application thereof | |
| CN116891810A (en) | Probiotic composition with blood sugar reducing effect and probiotic prebiotic composite preparation | |
| CN110959867A (en) | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof | |
| CN117660244A (en) | Composite probiotics for improving ulcerative colitis and application thereof | |
| CN115844019A (en) | Probiotic capable of regulating intestinal tract and application | |
| CN118086131A (en) | A six-linked probiotic freeze-dried powder preparation and its preparation method and application | |
| CN117050914A (en) | Acremonium muciniphilum and application thereof in improving GLP-1 secretion | |
| CN111011839A (en) | Ecological food for simulating excrement transplantation and preparation method and application thereof | |
| CN116869106A (en) | Probiotic solid beverage and preparation method thereof | |
| CN116445327A (en) | Hypolipidemic multielement probiotics and application thereof | |
| CN108795823B (en) | It is a kind of improve women pregnant and lying-in women's intestinal flora probiotics cultural method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |